(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group has received notice of registration of its 'AffiDX' SARS-CoV-2 antigen lateral flow test in the European Union, allowing it to place the product on the market for professional use in all 27 countries of the EU.
The AIM-traded firm said lateral flow antigen tests are intended to provide a "cost effective and rapid" means of identifying individuals with a high viral load, that means they are more likely to infect others with Covid-19.
It said the clinical data for its AffiDX test, reported 20 April, demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct